Mayer, Katharina http://orcid.org/0000-0002-3261-3333
Ndrepepa, Gjin
Schroeter, Mira
Emmer, Christopher
Bernlochner, Isabell
Schüpke, Stefanie
Gewalt, Senta
Hilz, Raphaela
Coughlan, John Joseph
Aytekin, Alp
Heyken, Clarissa
Morath, Tanja
Schunkert, Heribert
Laugwitz, Karl-Ludwig
Sibbing, Dirk
Kastrati, Adnan
Funding for this research was provided by:
Deutsches Herzzentrum München
Article History
Received: 17 November 2022
Accepted: 12 January 2023
First Online: 14 February 2023
Declarations
:
: Prof. Schunkert reports personal fees from MSD SHARP & DOHME, AMGEN, Bayer Vital GmbH, Boehringer Ingelheim, Daiichi Sankyo, Novartis, Servier, Brahms, Bristol-Myers Squibb, Medtronic, Sanofi Aventis and Synlab, grants from Astra-Zeneca, outside the submitted work. Prof. Sibbing reports personal fees from Bayer AG, Sanofi Aventis, Astra Zeneca, Pfizer, grants and personal fees from Roche Diagnostics, personal fees from Ferrer and Daiichi Sankyo, outside the submitted work. Prof. Schüpke reports grants from the Else Kröner Fresenius Stiftung (Else Kröner Memorial Sipendium), grants from the German Center for Cardiovascular Research (DZHK) for the ISAR-REACT 5 trial, personal fees from Bayer Vital GmbH, outside the submitted work. Dr. Bernlochner reports personal fees from Sysmex Europe GmbH, outside the submitted work. The other authors have no conflict of interest to declare.